Effect of gonadotropin-releasing hormone agonist and antagonist on steroidogenesis of low responders undergoing in vitro fertilization

Gynecological Endocrinology

Volumn 22, Issue 2, 2006, Pages 57-62

  Mohamed, Kamel Abdelhakim ^a   Davies, William A R ^a   Lashen, Hany ^b  

^a Centers for Assisted Reproduction (CARE at Northampton)   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Agonist; Antagonist; In vitro fertilization; Low responders; Steroidogenesis

Indexed keywords

BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; MIDAZOLAM; PETHIDINE; PROGESTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HORMONE DETERMINATION; HORMONE INHIBITION; HORMONE SYNTHESIS; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; OVARY FOLLICLE DEVELOPMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STEROIDOGENESIS; TREATMENT RESPONSE;

ADULT; BUSERELIN; CHORIONIC GONADOTROPIN; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEAL PHASE; LUTEINIZING HORMONE; MENOTROPINS; OVARIAN FOLLICLE; PROSPECTIVE STUDIES; STEROIDS;

EID: 33645790080     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500519260     Document Type: Article

References (28)

1. Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet 1984;ii:1284-1285.
2. Diedrich K, Diedrich C, Santos E, Zoll C, Al-Hasani S, Reissmann T, Krebs D, Klingmuller D. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994;9:788-791.
3. Felberbaum R, Albano C, Ludwig M, Riethmuller-Winzen H, Grigat M, Devroey P, Diedrich K. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum. Reprod 2000;15:1015-1020.
4. The European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001;16:644-651.
5. Olivennes F, Mannaerts B, Struijs M, Bonduelle M, Devroey P. Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report. Hum Reprod 2001;16:1588-1591.
6. Garcia-Velasco J, Isaza V, Vidal C, Landazabal A, Remohi J, Simon C, Pellicer A. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix). Hum Reprod 2001;16:2533-2539.
7. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, Devroey P. Ovarian stimulation with hMG: results of prospective randomized phase III European study comparing the luteinising hormone-releasing hormone (LHRH) antagonist cetorelix and LHRH-agonist buserelin. Hum Reprod 2000;15:526-531.
8. Minaretzis D, Alper N, Oskowitz S, Lobel S, Mortola J, Pavlou S. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells. Am J Obstet Gynecol 1995;172:1518-1525.
9. Akman M, Erden H, Tosun S, Bayazit N, Akosy E, Behceci M. Comparison of agonistic flare up protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod 2001;16:868-870.
10. Mohamed K, Davies W, Allsopp J, Lashen H. Agonist 'flare up' vs antagonist in the management of poor responders undergoing in vitro fertilization (IVF) treatment. Fertil Steril 2005;83:331-335.
11. Fleming R, Lloyd F, Herbert M, Fenwick J, Griffith T, Murdoch A. Effect of profound suppression of LH during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified FSH. Hum Reprod 1998;13:1788-1792.
12. Westergaard LG, Laursen SB, Anderson CY. Increased risk of early pregnancy loss by profound suppression of luteinising hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000;15:1003-1008.
13. Shoham Z, Balen A, Patel A, Jacob HS. Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients. Fertil Steril 1991;56:1048-1053.
14. Balasch J, Miro F, Burzaco I, Casamitjana R, Civico S, Ballesca JL, Puerto B, Vanrell JA. The role of luteinising hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human FSH. Hum Reprod 1995;10:1678-1683.
15. Kousta E, White DM, Piazzi A, Loumaye E, Franks S. Successful induction of ovulation and completed pregnancy using recombinant luteinizing hormone and follicle stimulating hormone in a woman with Kallman's syndrome. Hum Reprod 1996;11:70-71.
16. Fleming R, Rehka P, Deshpande N, Jamieson ME, Yates RWS, Lyall H. Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH. Hum Reprod 2000;15:1440-1445.
17. Esposito MA, Barnhart KT, Coutifaris C, Patrizio P. Role of periovulatory luteinizing hormone concentration during assisted reproductive technology cycles stimulated exclusively with recombinant follicle stimulating hormone. Fertil Steril 2001;75:519-524.
18. Ben-Amor A-F, on behalf of the Study Group (Tarlatzis B, Tavmergen E, Shoham Z, Szamatowicz M, Barash A, Amit A, Levitas I, Geva E). The effect of luteinizing hormone administered during late follicular phase in normo-ovulatory women undergoing in vitro fertilization. Hum Reprod 2000;15:46.
19. Cedrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J, Theron L, Wolf JP, Conord C, Clement P, et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2004;19:1979-1984.
20. de Jong D, Macklon N, Eijkemans M, Mannaerts B, Bennink H, Fauser B. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro ferilization using recombinant follicle stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon). Fertil Steril 2001;75:688-693.
21. Hillier SG, Whitelaw PF, Smyth CD. Follicular oestrogen synthesis: the 'two-cell two-gonadotropin' model revisited. Mol Cell Endocrinol 1994;100:51-54.
22. Latouche J, Crumeyrolle-Arias M, Jordan D, Kopp N, Augendre-Ferrante B, Cedard L, Haour F. GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology 1998;125:1739-1741.
23. Minaretzis D, Jakubowski M, Mortola J, Pavlou S. Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa lutein cells. J Clin Endocrinol Metab 1995;80:430-434.
24. Hsueh AJ, Erickson GF. Extrapituitary action of gonadotropin-releasing hormone: direct inhibition ovarian steroidogenesis. Science 1979;204:854-855.
25. Pellicer A, Miro F. Steroidogenesis in vitro of human granulose-luteal cells pretreated in vivo with gonadotropin-releasing hormone analogs. Fertil Steril 1990;54:590-596.
26. Bussenot I, Azoulay-Barjonet C, Parinaud J. Modulation of the steroidogenesis of cultured human granulosa-lutein cells by gonadotropin- releasing hormone analogs. J Clin Endocrinol Metab 1993;76:1376-1379.
27. Valbuena D, Pellicer A, Guanes PP, Remohi J, Simon C. Effect of disruption versus continuation of gonadotrophin-releasing agonist after human chorionic gonadotrophin administration on corpus luteum function in patients undergoing ovulation induction for in-vitro fertilization. Hum Reprod 1997;12:2118-2122.
28. The European Orgalutran Study Group, Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirilex in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000;15:1490-1498.